Swarup Kumar
Managing Partner and international intellectual property attorney
Gurugram, India
Joined March 2026
Summary
Seasoned intellectual property practitioner with a technical background: Kumar combines postgraduate studies in chemistry and law with two decades of hands-on IP practice, focusing on patent drafting, prosecution and litigation across technology verticals. kumasar+2
Active international IP leader and FICPI bureau member: elected Deputy Secretary General of FICPI in 2022 and serving in FICPI bureau activities and bilateral engagements, representing India in executive committees and global meetings. ficpi+2
Founder of a boutique techno-legal IP firm: launched Kumar & Sardana Associates in 2023 to provide tailored, business-friendly IP and technology law services, emphasizing customised patent and licensing advice rather than standardised offerings. kumasar+2
Published author and commentator on patentability and biotech IP issues: has written analyses on Section 3(d), gene patenting and therapeutic antibody patentability and regularly speaks/writes on patent law and IP practice management. ip-watch+2
Work
Education
Writing
Various IP practice articles (Remfry & Sagar)
January 1, 2019Contributions and articles on patent practice, biotechnology and IP enforcement published through Remfry & Sagar resources.
India: The Sunitinib Case
January 1, 2017Analysis of the Sunitinib patent litigation and related Indian patentability issues.
Patenting genes: how do India and the US compare?
January 1, 2016Comparative article on gene patenting approaches in India and the United States.
Patentability of Biological Material(s) - Essentially, Therapeutic Antibodies - in India
January 1, 2008A paper discussing Indian patent practice and jurisprudence related to the patentability of biological materials and therapeutic antibodies.
Scope, Implications Of Section 3(d) Of The Indian Patents Act, 1970 (As Amended)
June 1, 2007Analysis of Section 3(d) of the Indian Patents Act, discussing what constitutes a 'mere discovery', 'new form of known substance', and the requirement of increased efficacy for patentability, with reference to pharmaceutical cases.